Specialty pharmaceutical company Collegium Pharmaceutical, Inc. announced their focus on developing and bringing to market new pain management medications. Collegium's current portfolio includes a wide range of products, such as Xtampza ER, an oral formulation of oxycodone - a severe pain management drug - that is immune to exploitation and abuse; Nucynta ER and Nucynta IR, tapentadol-based medications that come in both extended-release and immediate-release formulations respectively; Belbuca, a buccal film containing buprenorphine; and Symproic, an oral formulation of naldemedine that treats opioid-induced constipation in adult patients suffering from chronic non-cancer pain. Originally named Collegium Pharmaceuticals, Inc., the company changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical's ticker is COLL
The company's shares trade on the NASDAQ stock exchange
They are based in Canton, Massachusetts
There are 201-500 employees working at Collegium Pharmaceutical
It is collegiumpharma.com
Collegium Pharmaceutical is in the Healthcare sector
Collegium Pharmaceutical is in the Drugs - Generic industry
The following five companies are Collegium Pharmaceutical's industry peers: